As a lifelong follower of the so-called ‘tau hypothesis,' TauRx Therapeutics chief executive Claude Wischik ploughed a lonely furrow for many years.
After the dramatic Phase III failure of Eli Lilly’s (NYSE: LLY) solanezumab late last year, followed by Merck & Co’s (NYSE: MRK) verubecestat in February, his Aberdeen, UK-based research team might have more company.
"I think the evidence was always there,” he told The Pharma Letter. “It's just taken time for the Americans to catch up.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze